AIDS Research

This letter is in response to the article "AIDS Investigators Cautiously Applauding Recent Advances" (S. Benowitz, The Scientist, Sept. 30, 1996, page 1). We have shown that HIV-specific transfer factor (TF) produces a far more rapid decrease in viral load as measured by the "old" polymerase chain reaction-HIV-RNA than do the currently recommended protease inhibitors or reverse transcriptase inhibitors such as AZT. Viral loads dropped from 80,000/mm³ or higher to 0 in three to four months,

Written byHugh Fudenberg
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

This letter is in response to the article "AIDS Investigators Cautiously Applauding Recent Advances" (S. Benowitz, The Scientist, Sept. 30, 1996, page 1). We have shown that HIV-specific transfer factor (TF) produces a far more rapid decrease in viral load as measured by the "old" polymerase chain reaction-HIV-RNA than do the currently recommended protease inhibitors or reverse transcriptase inhibitors such as AZT. Viral loads dropped from 80,000/mm³ or higher to 0 in three to four months, and clinical symptoms disappeared, regardless of how the AIDS was acquired.

These data have been presented by our group at three different symposia in 1996 (Keystone International Symposium on AIDS in March, the annual meeting of the Association of American Physicians in May, and the XI International Conference on AIDS in June). Similar results were obtained by my two collaborators (Dimitri Viza, a professor of immunology at the University of Paris, and Giancarlo Pizza, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies